WO2004111248A3 - Improved aav vector for gene therapy - Google Patents

Improved aav vector for gene therapy Download PDF

Info

Publication number
WO2004111248A3
WO2004111248A3 PCT/EP2004/006222 EP2004006222W WO2004111248A3 WO 2004111248 A3 WO2004111248 A3 WO 2004111248A3 EP 2004006222 W EP2004006222 W EP 2004006222W WO 2004111248 A3 WO2004111248 A3 WO 2004111248A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene therapy
aav vector
improved aav
eliminated
aav vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/006222
Other languages
French (fr)
Other versions
WO2004111248A2 (en
Inventor
Juergen Kleinschmidt
Oliver Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to US10/560,268 priority Critical patent/US7629322B2/en
Priority to EP04762994A priority patent/EP1664314B1/en
Priority to DE602004016871T priority patent/DE602004016871D1/en
Publication of WO2004111248A2 publication Critical patent/WO2004111248A2/en
Publication of WO2004111248A3 publication Critical patent/WO2004111248A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Described are recombinant AAV vectors characterized in that they carry capsid protein modification(s) resulting in a reduced or eliminated heparin binding function. The AAV vectors of the present invention are particularly suitable for gene therapy by systemic application, since (a) transduction of the liver is eliminated or at least drastically reduced and (b) the transduction efficiency of non-hepatic tissues is increased.
PCT/EP2004/006222 2003-06-11 2004-06-09 Improved aav vector for gene therapy Ceased WO2004111248A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/560,268 US7629322B2 (en) 2003-06-11 2004-06-09 AAV vector for gene therapy
EP04762994A EP1664314B1 (en) 2003-06-11 2004-06-09 Improved adeno-associated virus (aav) vector for gene therapy
DE602004016871T DE602004016871D1 (en) 2003-06-11 2004-06-09 FOR GENE THERAPY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03013169A EP1486567A1 (en) 2003-06-11 2003-06-11 Improved adeno-associated virus (AAV) vector for gene therapy
EP03013169.2 2003-06-11

Publications (2)

Publication Number Publication Date
WO2004111248A2 WO2004111248A2 (en) 2004-12-23
WO2004111248A3 true WO2004111248A3 (en) 2005-07-07

Family

ID=33185871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006222 Ceased WO2004111248A2 (en) 2003-06-11 2004-06-09 Improved aav vector for gene therapy

Country Status (5)

Country Link
US (1) US7629322B2 (en)
EP (2) EP1486567A1 (en)
AT (1) ATE409750T1 (en)
DE (1) DE602004016871D1 (en)
WO (1) WO2004111248A2 (en)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4969002B2 (en) 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン Compounds and methods for increasing rAAV transduction
AU2004227358B8 (en) 2003-03-31 2009-12-10 Targeted Genetics Corporation Compounds and methods to enhance rAAV transduction
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
ES2525067T3 (en) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
WO2008027084A2 (en) * 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
EP2018421B1 (en) * 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Scalable production method for aav
WO2007127464A2 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
ES2714007T3 (en) 2007-04-09 2019-05-24 Univ Florida Compositions of rAAV vectors that have tyrosine modified capsid proteins and methods for their use
US9725485B2 (en) * 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
WO2010011404A2 (en) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
WO2010093784A2 (en) * 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012109570A1 (en) * 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (en) 2011-04-22 2016-07-13 加利福尼亚大学董事会 Adeno-associated Virus Virions With Variant Capsid And Methods Of Use Thereof
MX374963B (en) 2011-04-29 2025-03-06 Selecta Biosciences Inc SYNTHETIC TOLEROGENETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES.
NZ701693A (en) 2012-04-18 2017-02-24 The Children’S Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
WO2013159036A1 (en) * 2012-04-19 2013-10-24 Oregon Health & Science University Adeno associated virus plasmids and vectors
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
US12358954B2 (en) 2012-05-15 2025-07-15 University Of Florida Research Foundation, Incorporated Capsid-modified rAAV vector compositions and methods therefor
EP2872183B1 (en) 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
BR122020023215B1 (en) 2013-05-03 2022-11-22 Selecta Biosciences, Inc COMPOSITION AND KIT OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGEN ANTIGEN
EP3492597A3 (en) * 2013-05-21 2019-08-28 University of Florida Research Foundation, Inc. Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
EP3003391B1 (en) 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
EP3113787B1 (en) * 2014-03-04 2019-12-04 University of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
PL3628334T3 (en) 2014-03-21 2023-12-18 Genzyme Corporation Gene therapy for retinitis pigmentosa
LT3137497T (en) 2014-05-02 2021-07-26 Genzyme Corporation AAV VECTORS FOR NETWORK AND CNS GENE THERAPY
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
JP7242180B2 (en) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for attenuating antiviral transduction vector immune responses
RU2716991C2 (en) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Aadc polynucleotides for treating parkinson's disease
KR20230145206A (en) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
WO2016133917A1 (en) 2015-02-16 2016-08-25 University Of Florida Research Foundation Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6836999B2 (en) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Adeno-associated virus mutants and how to use them
BR112017024514A2 (en) 2015-05-16 2018-07-24 Genzyme Corporation genetic editing of deep intronic mutations
US11273227B2 (en) 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
EP3384035A4 (en) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. ASSAYS FOR DETECTION OF NEUTRALIZING ANTIBODIES OF VAA
ES2934848T3 (en) 2015-12-11 2023-02-27 Univ Pennsylvania Scalable purification method for AAV8
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
CA3008264A1 (en) 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
SG11201808812RA (en) 2016-04-15 2018-11-29 Univ Pennsylvania Novel aav8 mutant capsids and compositions containing same
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11364308B2 (en) 2016-05-13 2022-06-21 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
KR102427379B1 (en) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. Compositions and methods for treating Huntington's disease
KR20240056729A (en) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
WO2018009814A1 (en) 2016-07-08 2018-01-11 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving rdh12
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CA3033856A1 (en) 2016-08-15 2018-02-22 Genzyme Corporation Methods for detecting aav
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
MX2019008143A (en) 2017-01-07 2020-01-13 Selecta Biosciences Inc Patterned dosing of immunosuppressants coupled to synthetic nanocarriers.
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
EP3585883A4 (en) 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated PROTEINS OF MODIFIED AAV CAPSIDES AND THEIR USES
RU2019130004A (en) 2017-03-01 2021-04-01 Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания GENE THERAPY FOR EYE DISEASES
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20260047644A (en) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 Chimeric molecules and uses thereof
WO2018200542A1 (en) 2017-04-24 2018-11-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
JP2020518259A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Huntington's disease treatment compositions and methods
IL316926A (en) 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinoses
EP3630986B1 (en) 2017-05-31 2026-03-25 The Trustees of The University of Pennsylvania Gene therapy for treating peroxisomal disorders
JP7766393B2 (en) 2017-06-14 2025-11-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Gene Therapy for Eye Disease
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3053154A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
JP2020534788A (en) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Adeno-associated virus capsid mutant and how to use it
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University IMMUNOREGULATORY MOLECULES AND THEIR USES
RU2770922C2 (en) 2017-09-20 2022-04-25 4Д Молекьюлар Терапьютикс Инк. Capsids of adeno-associated virus variants and methods of their application
EP3461836A1 (en) 2017-09-28 2019-04-03 Universität zu Köln Mutated adeno-associated viral capsid proteins for chemical coupling of ligands, nanoparticles or drugs via thioether binding and production method thereof
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
BR112020007157A2 (en) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. methods and compositions for the attenuation of viral transfer anti-vector igm responses
TW202413649A (en) 2017-10-16 2024-04-01 美商航海家醫療公司 Treatment of amyotrophic lateral sclerosis (als)
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111770999A (en) 2017-11-27 2020-10-13 4D分子治疗有限公司 Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CA3088323A1 (en) 2018-01-17 2019-07-25 Adrenas Therapeutics, Inc. Adeno-associated virus gene therapy for 21-hydroxylase deficiency
CN112384204B (en) 2018-02-26 2023-03-14 安托瑞斯公司 Tolerogenic liposomes and methods of use thereof
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20210019996A (en) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. Composition and method for the treatment of Parkinson's disease
EP3813845A4 (en) 2018-05-15 2022-10-26 President And Fellows Of Harvard College VIRAL VECTORS WITH IMPROVED GENE RELEASE PROPERTIES
CN112654370A (en) 2018-07-16 2021-04-13 西莱克塔生物科技公司 Methods and compositions for MMA constructs and vectors
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220154211A1 (en) 2019-02-25 2022-05-19 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
SG11202108044YA (en) 2019-02-25 2021-09-29 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
CN113795279B (en) 2019-03-04 2024-12-31 宾夕法尼亚州大学信托人 Neuroprotective gene therapy targeting the AKT pathway
EP3962537A1 (en) 2019-04-28 2022-03-09 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
SG11202111375RA (en) 2019-04-29 2021-11-29 Univ Pennsylvania Novel aav capsids and compositions containing same
EP3736330A1 (en) 2019-05-08 2020-11-11 European Molecular Biology Laboratory Modified adeno-associated virus (aav) particles for gene therapy
CN114206396A (en) 2019-05-28 2022-03-18 西莱克塔生物科技公司 Methods and compositions for attenuating an immune response against an antiviral transfer vector
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
AU2020299026A1 (en) * 2019-07-04 2022-01-20 Children's Medical Research Institute Methods and AAV vectors for in vivo transduction
KR20220128607A (en) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. Synthetic DNA Vectors and Methods of Use
EP4450514A3 (en) 2019-10-14 2025-04-09 Duke University Compositions comprising novel prokaryotic sodium channels and associated methods
WO2021092300A1 (en) 2019-11-08 2021-05-14 President And Fellows Of Harvard College Viral capsid polypeptides
US20230277685A1 (en) * 2020-04-08 2023-09-07 President And Fellows Of Harvard College TGFß THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES
EP4196170A1 (en) * 2020-08-14 2023-06-21 The Trustees of The University of Pennsylvania Novel aav capsids and compositions containing same
CA3191543A1 (en) * 2020-09-04 2022-03-10 Lei Cao Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
JP2023550581A (en) 2020-10-29 2023-12-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV capsid and composition containing the same
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022198038A1 (en) 2021-03-19 2022-09-22 Adrenas Therapeutics, Inc. Gene therapies for 21-hydroxylase deficiency
WO2022232267A1 (en) 2021-04-27 2022-11-03 The Trustees Of The University Of Pennsylvania Porcine-derived adeno-associated virus capsids and uses thereof
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
AU2022366947A1 (en) 2021-10-12 2024-05-02 Bridgebio Gene Therapy Llc Methods and compositions for treating leukodystrophies
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
JP2024545594A (en) 2021-11-14 2024-12-10 カーティザン セラピューティクス，インコーポレーテッド Multiple dosing with viral vectors
WO2023156530A1 (en) 2022-02-17 2023-08-24 Lysogene Gene therapy for neurodegenerative diseases
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20260021205A1 (en) 2022-07-15 2026-01-22 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
CN120813689A (en) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 Compositions and methods relating to immunoglobulin proteases and fusions thereof
CN117402222B (en) * 2023-11-17 2024-03-29 广州派真生物技术有限公司 Adeno-associated virus mutants and their applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
WO2003054197A2 (en) * 2001-12-21 2003-07-03 Medigene Ag A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
SI1496944T1 (en) * 2002-05-01 2009-02-28 Univ Florida Improved raav expression systems for genetic modification of specific capsid proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
WO2003054197A2 (en) * 2001-12-21 2003-07-03 Medigene Ag A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CALDWELL ELIZABETH E O ET AL: "Importance of specific amino acids in protein binding sites for heparin and heparan sulfate.", INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 28, no. 2, 1996, pages 203 - 216, XP002255704, ISSN: 1357-2725 *
DATABASE SWALL EMBL; 1 June 2003 (2003-06-01), GAO ET AL.: "Adeno-associated viruses undergo substantial evolution in primates during natural infections", XP002255706, Database accession no. Q808Y0 *
GAO GUANGPING ET AL: "Adeno-associated viruses undergo substantial evolution in primates during natural infections.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 100, no. 10, Q808Y0, 13 May 2003 (2003-05-13), May 13 2003 2003, pages 6081 - 6086, XP002255703, ISSN: 0027-8424 *
KERN A ET AL: "Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.", JOURNAL OF VIROLOGY, vol. 77, no. 20, October 2003 (2003-10-01), pages 11072 - 11081, XP002310361, ISSN: 0022-538X *
OPIE SHAUN R ET AL: "Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.", JOURNAL OF VIROLOGY, vol. 77, no. 12, 20 June 2003 (2003-06-20), pages 6995 - 7006, XP009018010, ISSN: 0022-538X *

Also Published As

Publication number Publication date
US20070036757A1 (en) 2007-02-15
US7629322B2 (en) 2009-12-08
EP1664314B1 (en) 2008-10-01
EP1664314A2 (en) 2006-06-07
WO2004111248A2 (en) 2004-12-23
ATE409750T1 (en) 2008-10-15
EP1486567A1 (en) 2004-12-15
DE602004016871D1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2004111248A3 (en) Improved aav vector for gene therapy
WO2004027019A3 (en) Improved raav expression systems for genetic modification of specific capsid proteins
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
WO2003046124A3 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2002012525A3 (en) Helper functions for recombinant vector production
WO2004081167A3 (en) Expression vectors comprising the mcmv ie2 promoter
WO2001011034A3 (en) Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
WO2002053703A3 (en) Aav2 vectors and methods
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
EP2330197A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2005033321A3 (en) Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1714975A3 (en) Gene and peptide for transcriptional repressor
WO2005049850A3 (en) Compositions and methods for systemic nucleic acid sequence delivery
WO2005021765A3 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
AU7077898A (en) Recombinant vectors derived from adeno-associated virus suitable for gene therapy
EP1845164A3 (en) Promoters for expression in modified vaccinia virus ankara
WO2002036627A3 (en) Interferons, uses and compositions related thereto
WO2002102316A3 (en) Histone deacetylase and methods of use thereof
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
WO2005023848A3 (en) Adenoviral epitopes
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2003093434A3 (en) Nanoarchaeum nucleic acid molecule
WO2006110240A3 (en) Gene transfer with adenoviruses having modified fiber proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004762994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004762994

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007036757

Country of ref document: US

Ref document number: 10560268

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10560268

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004762994

Country of ref document: EP